Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00148031 · ClinicalTrials.gov registry record · Phase 4
Improving Hepatitis C Treatment in Injection Drug Users
A Phase 4 study, sponsored by State University of New York - Upstate Medical University.
- Completed
- Registry status
- Phase 4
- Development phase
- 111
- Enrollment target
NCT00148031 is a Phase 4 study that has completed, run by State University of New York - Upstate Medical University. The registered enrollment target is 111 participants.
The verdict
NCT00148031, a Phase 4 study, has completed, sponsored by State University of New York - Upstate Medical University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 111 participants
- Enrollment target
Study Summary
The overall goal of the research project is to improve the outcome of medical care for injection drug users (IDUs) with Hepatitis C viral (HCV) infection. Hypothesis: An intervention designed to improve the rate of HCV treatment completion and sustained virologic response (SVR) in IDUs will increase access by integrating HCV medical care into a substance abuse treatment program.
Interventions
- DRUG Pegylated Interferon and Ribavirin
- BEHAVIORAL Psychosocial
- BEHAVIORAL On-site (MMT Clinic) HCV evaluation and treatment
- BEHAVIORAL Off-site HCV evaluation and treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2003-09 |
| Est. Completion | 2007-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00148031
The ClinicalTrials.gov registry entry for NCT00148031 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York - Upstate Medical University, which has 113 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pegylated Interferon and Ribavirin is the first listed.
NCT00148031 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00148031 about?
NCT00148031 is a clinical study titled "Improving Hepatitis C Treatment in Injection Drug Users". The overall goal of the research project is to improve the outcome of medical care for injection drug users (IDUs) with Hepatitis C viral (HCV) infection. Hypothesis: An intervention designed to improve the rate of HCV treatment completion and sustained virologic response (SVR) in IDUs will increas...
What is the current status of trial NCT00148031?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 111 participants. The study started on 2003-09. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00148031?
The interventions under investigation include: Pegylated Interferon and Ribavirin (DRUG), Psychosocial (BEHAVIORAL), On-site (MMT Clinic) HCV evaluation and treatment (BEHAVIORAL), Off-site HCV evaluation and treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT00148031?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.